Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo ® Use at ASH 2023
Learn more about Servier's leadership in mutant IDH inhibition at ASH booth #1347 BOSTON, Dec. 9, 2023 /PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will be presenting new data in acute myeloid leukemia (AML) at the... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 9, 2023 Category: Pharmaceuticals Tags: TRI TDS Source Type: news
Apixaban Prophylaxis Fails to Reduce Clots in Pediatric ALL
(MedPage Today) -- Prophylaxis with apixaban (Eliquis) failed to reduce the rate of venous thromboembolism (VTE) in children with newly diagnosed acute lymphoblastic leukemia or lymphoma, according to results from the phase III randomized PREVAPIX... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 21, 2023 Category: Cardiology Source Type: news
Poor Physical Function Persists in Childhood Cancer Survivors
MONDAY, Nov. 20, 2023 -- Despite changes in therapy, the prevalence of poor physical function has remained steady among childhood survivors of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 20, 2023 Category: Pharmaceuticals Source Type: news
Children With Down Syndrome More Vulnerable to Leukemia
WEDNESDAY, Nov. 1, 2023 -- While new treatments for leukemia have improved outcomes for many patients, children with Down syndrome have not benefited as much.These young people are at increased risk for acute lymphoblastic leukemia (ALL) and have... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 1, 2023 Category: General Medicine Source Type: news
Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023
WALTHAM, Mass., Sept. 29, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to share topline results from the... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 29, 2023 Category: Pharmaceuticals Tags: TRI CCA Source Type: news
Mum gets gut-wrenching leukemia diagnosis after kid's doctor spotted one thing
Laura Hendricks learned she had acute myeloid leukemia at the age of 40 after taking her sick children for a routine visit to the pediatrician. (Source: Daily Express - Health)
Source: Daily Express - Health - September 29, 2023 Category: Consumer Health News Source Type: news
Niche Interactions Lock Down Leukemia Cells
Researchers unravel the mystery of epithelial to mesenchymal transition in acute lymphoblastic leukemia with co-culture techniques, CRISPR-screening, and RNA sequencing. (Source: The Scientist)
Source: The Scientist - September 24, 2023 Category: Science Tags: News News & Opinion Source Type: news
Is Additional Treatment Needed Pretransplant in R/R AML? Is Additional Treatment Needed Pretransplant in R/R AML?
Experts recently debated whether additional intensive therapy can improve posttransplant outcomes for patients with acute myeloid leukemia who have residual disease after induction therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 11, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FLT3 Inhibitor Improves AML Survival With or Without Stem-Cell Transplant
(MedPage Today) -- HOUSTON -- Post-transplant maintenance with an FLT3 inhibitor significantly improved overall survival (OS) in FLT3-positive acute myeloid leukemia (AML), according to a subgroup analysis of a randomized trial.
Patients who... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 11, 2023 Category: Hematology Source Type: news
Paul Reubens Died of Respiratory Failure After Cancer Spread to His Lungs
Paul Reubens, star of the 1985 classic “Pee-wee’s Big Adventure,” had leukemia when he died in July at 70, according to his death certificate. Reubens’ cause of death was stated to be acute hypoxic respiratory failure, meaning his lungs were not producing enough oxygen. That condition was likely…#paulreubens #reubens #blast #peeweesbigadventure #batmanreturns #buffyvampireslayer #matilda #mysterymen #dunstonchecksin #cancerspread (Source: Reuters: Health)
Source: Reuters: Health - September 9, 2023 Category: Consumer Health News Source Type: news
Paul Reubens ’ Cause Of Death Confirmed
Paul Reubens, best known for portraying the iconic character Pee-wee Herman in TV shows, movies and on Broadway, was battling acute myelogenous leukemia, a form of blood cancer, and metastatic lung cancer when he died in June, according to his death certificate. The Blast was the first to report…#paulreubens #broadway (Source: Reuters: Health)
Source: Reuters: Health - September 9, 2023 Category: Consumer Health News Source Type: news
Intensive Pretransplant Consolidation in Older AML Fails to Improve Results
(MedPage Today) -- HOUSTON -- Intensive consolidation treatment before allogeneic stem-cell transplant did not improve outcomes in older patients with acute myeloid leukemia (AML), a retrospective comparison showed.
Relapse-free survival (RFS... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - September 7, 2023 Category: Surgery Source Type: news
More Intense ALL Therapy Improves Outcomes in Adolescents, Young Adults
(MedPage Today) -- HOUSTON -- Pediatric treatment protocols outperformed standard therapy for adolescents and young adults (AYAs) with Philadelphia chromosome-negative acute lymphocytic leukemia (ALL), a retrospective cohort study showed.
Patients... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 7, 2023 Category: Hematology Source Type: news
Fewer Complications Seen With Vitamin C, D Supplementation in AML
WEDNESDAY, Sept. 6, 2023 -- For patients with acute myeloid leukemia (AML), supplementation with vitamins C and D during chemotherapy may improve outcomes but may not improve overall survival (OS), according to a study published online Sept. 6 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 6, 2023 Category: Pharmaceuticals Source Type: news
FDA puts partial hold on Gilead ’s CD47 hopeful in AML
The FDA put a partial clinical hold on Gilead’s magrolimab for acute myeloid leukemia, a month after the company scrapped late-stage development of the CD47 candidate in myelodysplastic syndromes. Gilead said Monday morning it stopped screening and enrolling new patients in US…#fda #gilead #aml #partial #azacitidine #gileadsexpanded #unlock (Source: Reuters: Health)
Source: Reuters: Health - August 21, 2023 Category: Consumer Health News Source Type: news
